Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ALOX5AP
REST API REST API
Homo sapiens
ALOX5AP is differentially expressed in 250 experiments: 108 organism parts: lung, bone marrow, ... (106 more);, 218 disease states: normal, glioblastoma, ... (216 more);, 106 cell types 385 cell lines 27 compound treatments and 68 other conditions.
Synonyms FLAP
Orthologs alox5ap (Danio rerio)   Alox5ap (Mus musculus)   ALOX5AP (Gallus gallus)   AL5AP_BOVIN (Bos taurus)   Alox5ap (Rattus norvegicus)   alox5ap (Xenopus laevis)   ALOX5AP (Canis familiaris)   (Compare orthologs)
Gene Ontology Term leukotriene biosynthetic process, endoplasmic reticulum, protein binding, membrane, protein N-terminus binding, microsome, nucleus, protein heterodimerization activity, enzyme activator activity, nuclear envelope, protein homodimerization activity, integral to membrane, endoplasmic reticulum membrane, enzyme binding, nuclear membrane, arachidonate 5-lipoxygenase activity, cellular response to calcium ion, arachidonic acid binding, leukotriene production involved in inflammatory response, protein homotrimerization
InterPro Term Membr-assoc_MAPEG, 5_LipOase_AP
Gene-Disease Assocation STROKE, ISCHEMIC
UniProt Accession P20292
Search EB-eye ENSG00000132965
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-7224, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, E-GEOD-4717, ... (30 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
Jurkat
2
E-MTAB-62, E-MEXP-2197
MOLT4
2
E-MTAB-37, E-MTAB-62
Raji
2
E-MTAB-37, E-GEOD-96
SW480
2
E-MEXP-1014, E-GEOD-18005
K562
1
2
E-GEOD-96, E-GEOD-24147, E-MTAB-37
379 more value(s).


Cell type

studied in E-MEXP-1242, E-TABM-40, E-GEOD-22373, E-GEOD-3920, E-MEXP-750, ... (41 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3204, E-GEOD-3920
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
neutrophil
2
E-GEOD-12662, E-GEOD-3982
CD16 negative
1
E-GEOD-16836
HLA-DR positive T-cell
1
E-GEOD-6338
single positive thymocyte
1
E-GEOD-1460
100 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (58 experiments)

Factor Value U/D Experiments
glioblastoma
1
4
E-GEOD-4290, E-MEXP-567, E-GEOD-4412, E-MTAB-62, E-MTAB-37 ... (5 experiments)
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-16728
multiple myeloma
2
E-GEOD-6691, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
chronic lymphocytic leukemia
2
E-MTAB-37, E-GEOD-2466
colon carcinoma
2
E-MTAB-37, E-MTAB-62
212 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-571, E-GEOD-7400, E-GEOD-6907, E-GEOD-5741, ... (19 experiments)

Factor Value U/D Experiments
hydroxyurea
2
E-GEOD-6431, E-GEOD-571
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
nocodazole
1
E-GEOD-571
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
granulocyte-colony stimulating factor
1
E-GEOD-7400
dimethyl sulfoxide
1
E-GEOD-5824
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-2191, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-3140, E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-17385

Genotype
studied in E-GEOD-2466, E-GEOD-3624, E-GEOD-22593, E-GEOD-2292, E-TABM-321, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-12773, E-MEXP-1446, E-GEOD-22278, E-GEOD-9764, E-GEOD-837, ... (7 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (28 experiments)

Infection
studied in E-GEOD-9723, E-MEXP-561, E-GEOD-512

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-4525, E-GEOD-1460, E-GEOD-17636, E-GEOD-2487, ... (13 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-3697

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Processing time: 0.423 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM